AMA-VACC: Clinical trial assessing the immune response to SARS-CoV-2 mRNA vaccines and booster vaccination in siponimod treated patients with secondary progressive multiple sclerosis (P12-3.004)

Abstract

Listen

Translate article

<h3>Objective:</h3> We are aiming to understand the cellular and humoral immune responses to SARS-CoV-2 mRNA booster vaccinations in siponimod treated patients. <h3>Background:</h3> SARS-CoV-2 mRNA vaccines are a key factor fighting the COVID-19 pandemic across the globe. However, data are lacking on the efficacy of vaccination in patients with secondary progressive multiple sclerosis (SPMS) on disease-modifying therapies (DMTs) both over time and after a booster vaccination. <h3>Design/Methods:</h3> AMA-VACC is an open-label, three-cohort, prospective study in Germany with 41 multiple sclerosis patients currently treated with siponimod, any first-line DMT or without treatment at all in clinical routine. Cohort 1 receives SARS-CoV-2 mRNA vaccination while continuing their current siponimod treatment, cohort 2 interrupts siponimod treatment for the purpose of a full vaccination cycle and cohort 3 receives vaccination during continuous treatment with first-line DMTs (glatirameracetate, interferons, teriflunomide) or no current treatment in clinical routine. Primary endpoint is the rate of patients achieving seroconversion assessed by detection of serum neutralizing antibodies one week after SARS-CoV-2 mRNA vaccination. Furthermore, development and maintenance of SARS-CoV-2 specific T-cells is evaluated in all patients. Both parameters are analyzed in week one, month one and six month after initial vaccination cycle and one month after a booster vaccination. <h3>Results:</h3> After a positive first interim analysis showing both SARS-CoV-2 neutralizing antibodies and T-cell responses one week after complete vaccination in siponimod patients, final data of the study will be available in early 2023 including the effect of booster vaccination, which was received by 38 of 41 patients during study. <h3>Conclusions:</h3> This final analysis of the AMA-VACC trial will provide first longitudinal data on the immune response after SARS-CoV-2 mRNA vaccination and booster vaccination in siponimod treated SPMS patients and support physicians and patients to make an informed decision on the coordination of SARS-CoV-2 mRNA vaccination and SPMS treatment. <b>Disclosure:</b> Dr. Ziemssen has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Dr. Ziemssen has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Roche. Dr. Ziemssen has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis. Dr. Ziemssen has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for BMS Celgene. Dr. Ziemssen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Dr. Ziemssen has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Roche. Dr. Ziemssen has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Novartis. Dr. Ziemssen has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merck. Dr. Ziemssen has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Sanofi. Dr. Ziemssen has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for BMS Celgene. Dr. Ziemssen has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Biogen. Dr. Ziemssen has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for TEVA. The institution of Dr. Ziemssen has received research support from Biogen. The institution of Dr. Ziemssen has received research support from Novartis. The institution of Dr. Ziemssen has received research support from Merck. The institution of Dr. Ziemssen has received research support from Sanofi. The institution of Dr. Ziemssen has received research support from Celgene. Dr. Groth has received personal compensation for serving as an employee of Novartis Pharma GmbH. Dr. Winkelmann has received personal compensation for serving as an employee of Novartis Pharma GmbH. Prof. Bopp has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis. Prof. Bopp has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Prof. Bopp has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Teva. Prof. Bopp has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Merck. Prof. Bopp has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Pathios Therapeutics. The institution of Prof. Bopp has received research support from DFG (German Research Foundation). The institution of Prof. Bopp has received research support from BMBF. Prof. Bopp has received intellectual property interests from a discovery or technology relating to health care.